VANFLYTA

quizartinib · Daiichi Sankyo Inc.

Drug timelines are a Plus or Pro feature.

5 regulatory and trial events tracked for VANFLYTA, covering 2023-07-20 to 2026-08-19. Get the full timeline:

Most recent: EMA Authorised: Vanflyta (quizartinib dihydrochloride) — Daiichi Sankyo Europe GmbH